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Abstract 24 
 25 
Carrying at least one apolipoprotein E 4 allele (E4+) is the main genetic risk factor for 26 
Alzheimer's disease (AD). Epidemiological studies support that consuming fatty fish rich in 27 
docosahexaenoic acid (DHA: 22: 6 ω3) is protective against development of AD. However, this 28 
protective effect seems not to hold in E4+. The involvement of APOE genotype on the 29 
relationship between DHA intake and cognitive decline could be mediated through cholesterol. 30 
Many studies show a link between cholesterol metabolism and AD progression. In this study, we 31 
investigated whether cholesterol metabolism is improved in E3+ and E4+ mice consuming a diet 32 
rich in DHA. Plasma cholesterol was 36% lower in E4+ mice compared to E3+ mice fed the 33 
control diet (p=0.02) and in the liver there was a significant genotype effect where cholesterol 34 
levels were 18% lower in E4+ mice than E3+ mice. The low-density lipoprotein receptor was 35 
overexpressed in the liver of E4+ mice. Plasma cholesterol levels were 33% lower after the DHA 36 
diet (p=0.02) in E3+ mice only and there was a significant diet effect where cholesterol level was 37 
67% lower in the liver of mice fed DHA. Mice fed the DHA diet also had 62% less lipolysis 38 
stimulated lipoprotein receptor expression in the liver compared to mice fed the control diet 39 
(p<0.0001) but there was no genotype effect. These findings suggest that plasma and liver 40 
cholesterol homeostasis and the receptors regulating uptake of cholesterol in the liver are 41 
modulated differently and independently by APOE allele and DHA intake.  42 
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1. Introduction 46 
Alzheimer’s disease (AD) is a neurodegenerative disease modulated by several 47 
environmental, physiological and genetic risk factors. The main genetic risk of AD is carrying an 48 
4 allele of apolipoprotein E (E4+). Production of the apolipoprotein E (apoE) protein is 49 
controlled by the APOE gene for which three different alleles are recognized: 2, 3 and 4 [1]. 50 
ApoE production occurs primarily in the liver and the brain and to a lesser extent, in 51 
macrophages [2-3]. ApoE plays a pivotal role in lipid homeostasis: it regulates cholesterol, 52 
triglyceride and phospholipid transport and metabolism via interactions with receptors of the 53 
LDL family [4]. The low-density lipoprotein receptor (LDLR) is the receptor responsible for the 54 
uptake of cholesterol-rich LDL particles [5]. However, LDLR is not the only apoE receptor 55 
involved in lipoprotein metabolism. The lipolysis-stimulated lipoprotein receptor (LSR) is a 56 
multimeric receptor in the liver that recognizes both apoB and apoE and plays a role in the 57 
clearance of both triglycerides-rich particles and LDL [6]. 58 
Cholesterol is a key structural molecule of cellular membranes and it is important for brain 59 
function because it is involved in synaptic plasticity, learning, memory and neuronal integrity 60 
during aging [7]. Molecular evidence points towards a link between peripheral cholesterol 61 
metabolism and AD since high levels of plasma cholesterol in mid-life has been associated with a 62 
higher risk of developing AD [8]. There is currently no drug to cure or delay cognitive deficits 63 
associated with late onset AD supporting that prevention strategies are urgently needed. A diet 64 
containing docosahexaenoic acid (DHA), a n-3 polyunsaturated fatty acid (PUFA) concentrated 65 
in fatty fish, have shown promising results in animals to prevent onset of cognitive decline but in 66 
humans, results are less consistent [9]. The mechanisms explaining why fortification of the diet 67 
with DHA might help to prevent cognitive decline might stand on its role in neuronal 68 
differentiation [10], neurogenesis [11] and protection against synaptic loss [12]. However, it 69 
seems that E4+ are not protected against cognitive decline when eating DHA [13-14]. Human 70 
and animal studies suggest that higher plasma cholesterol levels are associated with higher risk of 71 
cognitive decline [8,15]. Since apoE protein plays a key role in plasma cholesterol homeostasis 72 
and since apoE genotype modulate plasma DHA response to a DHA diet [16], we hypothesize 73 
that apoE genotype modify plasma cholesterol levels under a DHA diet. In order to elucidate the 74 
multi-organ mechanisms linking APOE genotype with cholesterol metabolism, animal models are 75 
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required. To date, mice knocked-in for human APOE isoforms provide a unique and useful tool 76 
to characterize dysfunction in lipid metabolism according to APOE genotype [17]. Therefore, in 77 
this study, we sought to investigate in E3+ and E4+ mice whether there is an interaction between 78 
a diet rich in DHA and E4 allele on peripheral cholesterol level and on proteins involved in 79 
cholesterol metabolism.  80 
2. Materials and Methods 81 
2.1 Animals 82 
APOE-targeted replacement mice expressing human APOE allele were purchase at 83 
Taconic (Hudson, NY, USA). From weaning to 4 months of age, mice were fed a regular chow 84 
diet containing 66% (w/w) carbohydrate, 5 % (w/w) fat, 20% (w/w) proteins (Teklad 2018, 85 
Harlan Laboratories, IN, USA). At 4 months, half of the mice were fed a diet containing 0.7% 86 
(w/w) DHA (DHA diet, Research Diets Inc New Brundswick, NJ, USA) while the other half 87 
remained on regular chow diet (n = 10-14/genotype). At 12 months of age, mice were 88 
anesthetised with ketamine/xylazine and 100 µL of blood was collected by cardiac puncture in a 89 
lithium heparin tube (Becton Dickinson, Franklin Lakes, NJ, USA) and centrifuged at 4°C for 5 90 
min at 2000 g, and plasma was collected and frozen at -80°C. Mice were immediately perfused in 91 
the heart with 50 ml 0.1 M PBS buffer. Liver was fast frozen on dry ice. All experiments were 92 
performed in accordance with the Canadian Council on Animal Care and were approved by the 93 
Institutional Committee of the Centre Hospitalier de l’Université de Laval (CHUL). 94 
 95 
2.2 Cholesterol analysis  96 
Liver was pulverized in powder with a biopulverizer (Biospec products, Bartlesville, OK, 97 
USA). Total lipids were extracted using the Folch et al. method from a 50 mg sample of liver 98 
powder [18]. The liver total lipid extract was then saponified using 1 M KOH/methanol and 99 
heated at 90°C for 1 hour. To quantify cholesterol, 250 µg of 5 α-cholestane (10 mg/mL) was 100 
added to the samples before lipid extraction and area under the curve was used to quantify total 101 
cholesterol in the samples. Cholesterol was analysed by gas chromatography. Plasma cholesterol 102 
was measured by a commercially available kit (DIM chol cholesterol flex ; Siemens) on a clinical 103 
analyser. 104 
 105 
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2.3 Western immunoblotting 106 
Total proteins were extracted from a sample of 50 mg of liver powder using 1 ml of 107 
extraction buffer containing 50 mM Tris-HCL pH 7.4, 2.5 mM EDTA, 150 mM NaCL, 0.5% 108 
(w/v) and protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). Tissue was 109 
sonicated and centrifuged for 20 min at 100 000 g at 4°C. 20 µg of proteins were loaded on a 110 
10% Mini-PROTEAN® TGX Stain-FreeTM polyacrylamide gel (Bio-Rad, Laboratories, 111 
Hercules, CA, USA). After electrophoresis, the proteins were transferred onto a polyvinylidene 112 
difluoride membrane (Bio-Rad, Laboratories, Hercules, CA, USA). Membranes were blocked 113 
with 5% (w/v) milk in 0.05% (v/v) TBS-tween for 60 min at room temperature, and thereafter 114 
incubated overnight at 4°C with the following primary antibodies: LDLR (1:1000, Novus, 115 
Vancouver, Canada), LSR (1:500, Sigma, Oakville, Canada), LRP1 (1:2000, Abcam, Cambridge, 116 
UK), ApoE (1:500, Novus, Vancouver, Canada). Bands were revealed by chemiluminescence 117 
with Luminata Crescendo HRP substrate (EMD Millipore, Billerica, MA, USA) using a 118 
peroxidase-conjugated secondary antibody (1:2000, Cell Signaling Technology, Danvers, MA, 119 
USA). Densitometry was assed using ChemiDoc™ MP System (Bio-Rad, Laboratories, 120 
Hercules, CA, USA). Total proteins were quantified with the Stain-FreeTM technology (Bio-Rad 121 
Laboratories, Hercules, CA, USA) and used as loading control. This technology is a more robust 122 
quantification technique compared to β-actin for Western immunoblotting [18-19]. Protein levels 123 
of E3+ mice fed the control diet were standardised at 100%. 124 
 125 
2.4 Plasma apoE quantification 126 
ApoE levels were measured in plasma from mice expressing one of the two human APOE 127 
alleles using a sandwich ELISA (Abcam Cambridge, UK). Briefly, plasma sample were diluted 128 
1:200 into 1X Diluent N that was provided with the kit. 50 µL of sample or standard were loaded 129 
into a 96-well plate that had been coated with an anti-apoE antibody. Levels of apoE were 130 
performed in duplicate and quantification was performed using the standard curve. Absorbance 131 
was measured at 450 nm using a VICTORTM X Multilabel Plate Reader (PerkinElmer, Waltham, 132 
MA, USA). 133 
 134 
2.5. Liver protein gene expression 135 
RNA in the liver powder was extracted using the RNeasy Minikit (Qiagen, Venlo, 136 
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Netherlands). RNA purity and integrity were assessed on an Agilent 2100 Bioanalyzer (Agilent 137 
Technologies, Santa Clara, CA, USA). Quantitative PCR was performed at the RNomics 138 
Platform, Laboratoire de Génomique Fonctionnelle, University of Sherbrooke, QC, Canada. 139 
cDNA synthesis was performed using 1.3 µg of RNA with Transcriptor reverse transcriptase, 140 
random hexamers and dNTPs (Roche Diagnostics, Basel, Switzerland). Quantitative PCR were 141 
conducted with 10 ng cDNA and 200 nM primer pair solution on a CFX-384 termocycler (Bio-142 
Rad, Laboratories, Hercules, CA, USA). Relative expression calculations of the candidate genes 143 
were performed using the housekeeping genes Pum1, Sdha and Txnl4b for mouse cDNA. 144 
 145 
2.6 Statistical analysis 146 
Data are expressed as means ± SEM. Two-way ANOVA with genotype and diet as fixed 147 
factors were performed. When there was a significant genotype × diet interaction, subgroup 148 
analysis with t-test were performed to compare differences between genotypes in each dietary 149 
group separately and to compare differences between diets in each genotype group separately. 150 
Statistical significance was set at p<0.05. 151 
3. Results 152 
3.1 E3+ mice fed the DHA diet have lower plasma cholesterol levels compared to E3+ mice 153 
fed the control diet. 154 
For plasma cholesterol, there was a trend towards a diet x genotype interaction (p=0.054). 155 
Plasma cholesterol was 36% lower in E4+ mice compared to E3+ mice fed the control diet 156 
(p=0.02, Fig 1). E3+ mice fed the DHA diet had 33% lower plasma cholesterol compared to E3+ 157 
mice fed the control diet (p=0.025, Fig 1). There was no such significant diet effect in E4+ mice 158 
(Fig 1). These results suggest that E4+ mice did not respond to the DHA diet in terms of plasma 159 
cholesterol lowering. 160 
3.2 E3+ and E4+ fed the DHA diet have lower hepatic lipoprotein receptor protein and 161 
mRNA levels compared E3+ and E4+ mice fed the control diet. 162 
There was no diet x genotype interaction on the protein levels and mRNA expression of 163 
the LDLR, LSR and low density lipoprotein receptor-related protein 1 (LRP1). There was a 164 
genotype effect on hepatic LDLR protein levels and its mRNA expression levels (p=0.004 and 165 
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p=0.026, Fig 2A and 2B). LDLR protein level was 60-66% higher in E4+ mice than E3+ mice 166 
whereas mRNA expression level was 23-33% higher in E4+ mice than E3+ mice and this effect 167 
was independent of the diet (Fig 2A and 2B). There was no diet effect on the protein level of 168 
LDLR but there was a 35-40% lower expression of LDLR mRNA in mice fed the DHA diet 169 
compared to the control diet (p<0.0001, Fig 2A and 2B). There was a diet effect for LSR protein 170 
level and its mRNA expression level (p<0.0001 and p=0.002 Fig 2C and 2D). LSR protein level 171 
was 62% lower in mice fed the DHA diet than mice fed the control diet whereas mRNA 172 
expression level was 23-33% lower in mice fed DHA than mice fed the control diet. The diet 173 
effects were independent from genotype (Fig 2C and 2D). There was no diet nor genotype effect 174 
for LRP1 protein levels (Fig 2E). 175 
 176 
3.3 E4+ mice have lower plasma apoE and higher liver apoE levels compared to E3+ mice 177 
There was no diet x genotype interaction on the plasma and liver levels of apoE. There 178 
was however an independent genotype effect on apoE levels in the plasma and the liver 179 
(p<0.0001 and p=0.019, Fig 3A and 3B). Plasma apoE level was ~ 35% lower in E4+ mice than 180 
E3+ mice (Fig 3A), whereas in the liver it was ~ 25% higher in E4+ mice than E3+ mice (Fig 181 
3B). 182 
 183 
3.4 E3+ and E4+ fed the DHA diet have lower liver cholesterol levels compared to E3+ and 184 
E4+ mice fed the control diet. 185 
There was no diet x genotype interaction on the level of cholesterol in the liver. There was a 186 
diet effect and a genotype effect for cholesterol level in the liver (p<0.0001 and p=0.015, Fig 4). 187 
Cholesterol levels were ~ 67% lower in mice fed the DHA diet than mice fed the control diet (Fig 188 
4). Moreover, cholesterol level in the liver was ~18% lower in E4+ mice than E3+ mice (Fig 4). 189 
4. Discussion  190 
Since apoE is a protein involved in cholesterol and fatty acid metabolism, we sought to 191 
evaluate whether there was an interaction between E4+ genotype and a diet containing DHA. Our 192 
results support that plasma and liver cholesterol homeostasis and the receptors regulating uptake 193 
of cholesterol in the liver are differently and independently modulated by APOE allele and DHA 194 
intake.  195 
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Our results showed that plasma cholesterol levels were lower in E4+ mice than E3+ mice. 196 
Previous studies did not report difference in plasma cholesterol levels between E4+ mice and 197 
E3+ mice aged of 4 or 12 months [20-21] . One explanation as to why our results differ from the 198 
one published by other groups might rely on the diet composition: our diet had 5% fat and no 199 
extra added vitamins while the diet of the other investigators contained 21% fat [21] or vitamins 200 
[22]. Indeed, dietary fat composition and vitamin E supply affect hepatic lipogenesis and 201 
lipoprotein oxidation [22-23] Our results are also opposite to what is reported in humans where 202 
plasma total cholesterol levels were 2.3-6.5% higher in E4+ than E3+ [16, 24-25]. However, 203 
cholesterol metabolism differs between mice and humans since mice are deficient in cholesteryl 204 
ester transfer protein (CETP), which is involved in the transfer of cholesteryl ester from high-205 
density lipoprotein (HDL) to other lipoproteins. Hence, in mice, cholesterol is mainly carried by 206 
HDL particles but in humans, LDL mainly carries cholesterol. In another study, introducing 207 
human CETP gene into mice reduced HDL levels while VLDL and LDL cholesterol were 208 
slightly increase [26-27]. Unfortunately, in this study, we did not perform a lipoprotein profile 209 
because we did not collect enough blood at sacrifice so we are not in a position to confirm this 210 
hypothesis.  211 
Our results also showed that only E3+ mice fed the DHA diet have lower plasma 212 
cholesterol levels. It has previously been reported that fish oil lowers the secretion and synthesis 213 
of lipoproteins in chick, rabbit and monkeys [30-32]. However, to our knowledge, there is 214 
currently no study reporting lipoproteins receptors in the liver of E3+ and E4+ mice fed a DHA 215 
diet. To understand why plasma cholesterol levels were not lowered in E4+ mice fed the DHA 216 
diet, we investigated liver cholesterol receptors.  217 
One key receptor to cholesterol homeostasis is the LDLR because it mediates removal of 218 
LDL, it is involved in chylomicron remnants uptake by binding with apolipoprotein B-100 and 219 
apoE and it plays a major role in regulating plasma cholesterol levels [33]. Here, we report for the 220 
first time that liver mRNA and protein LDLR expressions were higher in E4+ mice than E3+ 221 
mice. It is known that E4+ mice have higher levels of LDL compared to E3+ mice [34]. Hence, 222 
the overexpression of LDLR in the liver of E4+ mice may be a compensatory mechanism to 223 
favor LDL removal from the plasma. Moreover, this process might be explained by a 224 
downregulation of the liver X receptor (LXR) pathway in E4+ mice. LXR is a transcriptional 225 
 9 
factor targeting many genes such as APOE and inducible degrader of the LDLR (IDOL) [35-36], 226 
the latter mediates the ubiquitylation and degradation of LDLR. Mice infected with an adenoviral 227 
vectors encoding the overexpression of mouse IDOL had lower LDLR protein and higher plasma 228 
cholesterol levels [36]. In this study, E4+ mice had higher LDLR, lower cholesterol and lower 229 
plasma apoE, all of which are in line with a downregulation of LXR pathway. Hence, to confirm 230 
this hypothesis, further experiments using hepatocytes isolated from E3+ and E4+ mice should 231 
be used to investigate the LXR pathway.  232 
Another study using mice heterozygous for the human LDLR minigene were bred to mice 233 
homozygous for either the human E3+ or E4+ allele. Mice were fed a diet with similar fat 234 
content compared to our diet. The authors reported lower plasma cholesterol levels in E4+ mice 235 
that were overexpressing LDLR compared to E4+ mice that were not overexpressing LDLR [37]. 236 
Hence, overexpression of LDLR in E4+ mice partially explains why plasma cholesterol levels 237 
were lower than E3+ mice in our study. 238 
Compared to mice fed the control diet, the ones consuming DHA had lower levels of 239 
LDLR mRNA, but protein expression was unchanged. This result suggests that the diet effect 240 
was more at the translational levels but posttranslational mechanisms might also be involved 241 
since LDLR protein expression was unchanged. Mice consuming DHA also had lower LSR 242 
receptor protein levels and mRNA expression compared to mice fed the control diet and this was 243 
independent of APOE allele. This receptor is mainly involved in postprandial lipemia regulation 244 
and its activity is regulated by plasma free fatty acids (FFA). When FFA interact with LSR, its 245 
conformation is modify to expose a lipoprotein-binding site [38]. Oleate and palmitate 246 
demonstrated the strongest response [38] whereas the response of DHA has never been 247 
investigated. Here, we speculate that DHA could improve the activity of LSR, resulting in a 248 
lower protein expression. The biochemical assay developed by Mann et al using purified plasma 249 
membranes from rat hepatocytes should be used to investigate this hypothesis [38]. In LSR+/- 250 
mice, lipoprotein clearance was lower hence leading to higher plasma total cholesterol levels [6], 251 
[39]. Since in this study, plasma cholesterol levels are lower in E3+ mice fed the DHA diet 252 
compared to the E3+ mice fed the control diet, we expected higher levels of LSR in mice fed the 253 
DHA diet but we report the opposite. However, mice were not fasted and LSR might not be the 254 
key receptor to explain the diet effect in E3+ mice. Another hypothesis as to how DHA could 255 
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have lowered plasma cholesterol is with regards to lower intestinal absorption. Interestingly, two 256 
studies reported lower cholesterol absorption in rat and monkey after consuming a diet with n-3 257 
PUFAs [40-41].   258 
The mechanisms underlying the relationship between DHA intake, blood and liver 259 
cholesterol levels are not fully understood. One study in rats reported that dietary n-3 PUFA 260 
might improve LDL clearance by the liver without changing hepatic LDLR expression [42]. This 261 
is consistent with our results since the LDLR protein level was not modified by the diet while 262 
cholesterol levels was lower in the plasma. Our result might also be explained by higher hepatic 263 
LDLR activity since one study reported a higher hepatic LDLR activity in rats fed a DHA diet 264 
[42]. Another root of explanation for difference in response to the DHA diet in terms of plasma 265 
cholesterol levels between E3+ and E4+ mice involves the levels of apoE proteins in the plasma 266 
and in the liver of E4+ mice. Indeed, apoE levels were lower in the plasma and higher in the liver 267 
of E4+ mice than E3+ mice and apoE is a protein binding to LDLR and LSR so this could have 268 
changed the number of binding site for clearing lipids from the blood. Our results with regards to 269 
apoE levels in the plasma are similar to the one reported in E4+ mice from other investigators 270 
[43], [44] and parallel the results in humans [45]. However, in the liver, apoE levels were higher 271 
in E4+ mice than E3+ mice and this was independent of the diet. Liver LDLR overexpression in 272 
E4+ mice could increase apoE uptake and transport in the liver.  273 
One intriguing result we obtained was the 67% lower liver cholesterol levels in E3+ and 274 
E4+ mice fed the DHA diet. There was also a genotype effect mainly driven by the 22% lower 275 
cholesterol levels in the liver of E4+ mice fed the control diet compared to E3+ mice fed the 276 
same diet. This range of lower liver cholesterol level was also reported by Vasandani et al. [46] in 277 
a LDLR knock out mouse model fed n-3 PUFA and in rats fed a DHA enriched diet [46-47]. 278 
Since LSR was originally identified as a liver receptor for the uptake of both trigycerides-rich 279 
particles and LDL, lower expression of LSR in the liver might contribute to explain why 280 
cholesterol levels were lower in the liver of mice fed DHA. Moreover, bile acid synthesis is a 281 
major pathway for hepatic cholesterol catabolism. In line with this, one study have shown that a 282 
diet enriched with DHA increases biliary secretion of cholesterol and other lipids in rats [47]. 283 
These speculations clearly need further investigations in E3+ and E4+ mice. 284 
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In conclusion, our results show that E4+ allele is associated with an overexpression of LDLR in 285 
the liver, lower plasma apoE levels, higher liver apoE levels and lower plasma cholesterol levels. 286 
Moreover, DHA intake has lowered cholesterol in the plasma of E3+ mice only and lowered 287 
cholesterol levels in the liver of E3+ and E4+ mice. mRNA or protein expression of lipoprotein 288 
receptors are lower with DHA intake. Taken together, our results showed that plasma and liver 289 
cholesterol homeostasis and the receptors regulating uptake of cholesterol in the liver are 290 
independently modulated by APOE allele and DHA intake. In light of these results, brain 291 
cholesterol homeostasis in response to a DHA supplement and in relation with cognition needs to 292 
be performed. This would be particularly relevant in E4+ since they are not protected against 293 
cognitive decline when eating DHA. 294 
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FIGURE LEGENDS 463 
Fig 1: Apolipoprotein E 4 (APOE4) allele and docosahexaenoic acid (DHA) diet are associated 464 
with decreased plasma cholesterol. Plasma cholesterol levels in mice knock-in for APOE3 allele 465 
(E3, open bars) or in mice knock-in for APOE4 allele (E4, solid bars) fed a control or a DHA 466 
diets were measured as described in materials and methods. Results are mean ± SEM (n=6/group) 467 
and P values are indicated when there was a significant result after comparing E4 to E3 groups. 468 
Two-way ANOVA were performed with apolipoprotein E genotype and diet as fixed factors. 469 
Subgroup analyses with t-test were performed. 470 
Fig 2: Apolipoprotein E 4 (APOE4) allele and docosahexaenoic acid (DHA) diet are associated 471 
with lower liver lipoprotein receptor expression. Membranes liver extracts from 12 months old 472 
mice knock-in for APOE3 allele (E3, open bars, n=8-10) and mice knock-in for APOE4 allele 473 
(E4, solid bars, n=8-10) fed a DHA or control diets were analyzed by western immunoblotting 474 
for protein levels of LDLR (A), LSR (C) and LRP1 (E). Top panels: representative blots for 475 
individual animals. Bottom panels: bar graphs of mean ± SEM values. Liver samples were 476 
analysed by quantitative RT-PCR for mRNA levels of LDLR (B) and LSR (D) in E3 and E4 mice 477 
on DHA or control diets. Two-way ANOVA were performed with apolipoprotein E genotype and 478 
diet as fixed factors. 479 
Fig 3: Apolipoprotein E 4 (APOE4) allele is associated with impaired liver and plasma apoE 480 
levels. Membranes liver extracts from 12 months old mice knock-in for APOE3 allele (E3, open 481 
bars, n=8-10) and mice knock-in for APOE4 allele (E4, solid bars, n=8-10) fed a 482 
docosahexaenoic acid (DHA) or control diets were analyzed by western immunoblotting for 483 
protein levels of apoE (B). Top panels: representative blots for individual animals. Bottom 484 
panels: bar graphs of mean ± SEM values. Plasma apoE levels were measured in 12 months old 485 
E3 mice and E4 mice (A) as described in materials and methods. Mean ± SEM values are shown. 486 
Two-way ANOVA were performed with apolipoprotein E genotype and diet as fixed factors. 487 
Fig 4: Apolipoprotein E 4 (APOE4) allele and docosahexaenoic acid (DHA) diet are associated 488 
with decreased liver cholesterol. Liver cholesterol levels were measured in 12 months old mice 489 
knock-in for APOE3 allele (E3, open bars, n=8-10) and in mice knock-in for APOE4 allele (E4, 490 
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solid bars, n=8-10) fed a DHA or control diets as described in materials and methods. Two-way 491 
ANOVA were performed with apolipoprotein E genotype and diet as fixed factors. 492 
 493 
